<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322877</url>
  </required_header>
  <id_info>
    <org_study_id>125230</org_study_id>
    <nct_id>NCT04322877</nct_id>
  </id_info>
  <brief_title>Cardiac Resynchronisation Therapy In Patients With Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping</brief_title>
  <official_title>Cardiac Resynchronisation Therapy In Patients With Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac Resynchronisation Therapy (CRT) is a specialist pacemaker procedure that aims to
      improve the efficiency of the heartbeat. This treatment is used routinely in patients with
      heart failure and a delay in electrical conduction across the heart seen on the surface ECG
      (heart tracing). The investigators aim to assess acute response to CRT and compare different
      methods of delivering CRT using hemodynamic data from invasive dP/dTmax and electroanatomical
      data from either invasive mapping or non-invasive body surface mapping.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in LV dP/dTmax &gt;10 percent during temporary multisite pacing</measure>
    <time_frame>Intra-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrical dyssynchrony measured from electro-anatomical mapping</measure>
    <time_frame>Intra-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Body surface mapping and temporary pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter-based mapping and temporary pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Temporary pacing Study</intervention_name>
    <description>Temporary delivery of CRT</description>
    <arm_group_label>Body surface mapping and temporary pacing</arm_group_label>
    <arm_group_label>Catheter-based mapping and temporary pacing</arm_group_label>
    <other_name>Electrophysiology study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic CT</intervention_name>
    <description>As part of non-invasive mapping protocol</description>
    <arm_group_label>Body surface mapping and temporary pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Acute hemodynamic study</intervention_name>
    <description>Measurement of invasive dP/dTmax</description>
    <arm_group_label>Body surface mapping and temporary pacing</arm_group_label>
    <arm_group_label>Catheter-based mapping and temporary pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive body surface mapping</intervention_name>
    <description>Cardioinsight body surface mapping</description>
    <arm_group_label>Body surface mapping and temporary pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Invasive catheter-based mapping</intervention_name>
    <description>Invasive electroanatomical mapping</description>
    <arm_group_label>Catheter-based mapping and temporary pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Male or Female, aged 18 years or above.

          -  Either 1) has CRT system in situ or 2) has a planned CRT system implant or 3) has a
             planned upgrade to CRT from a standard pacemaker

          -  NYHA grade II-IV heart failure

          -  LVEF&lt;35%

          -  Intrinsic QRS duration &gt;120ms

          -  On optimum medical therapy for heart failure

          -  Female participants of child bearing potential must be willing to ensure that they or
             their partner use effective contraception during the study and for 3 months thereafter

          -  Able (in the Investigators opinion) and willing to comply with all study requirements.

          -  Willing to allow his or her General Practitioner and consultant, if appropriate, to be
             notified of participation in the study.

        Exclusion Criteria:

          -  Female participants who is pregnant, lactating or planning pregnancy during the course
             of the study.

          -  Scheduled elective surgery or other procedures requiring general anaesthesia during
             the study.

          -  Participant who is terminally ill or is inappropriate for placebo medication

          -  Any other significant disease or disorder which, in the opinion of the Investigator,
             may either put the participants at risk because of participation in the study, or may
             influence the result of the study, or the participant's ability to participate in the
             study.

          -  Rate uncontrolled atrial fibrillation precluding a cMR

          -  Significant peripheral vascular disease precluding an EP study

          -  A contraindication to anticoagulation

          -  A prosthetic aortic or tricuspid valve

          -  Significant Aortic valve disease

          -  Known LV thrombus

          -  Insufficient capacity to consent to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher A Rinaldi, MBBS MD FHRS</last_name>
    <phone>02071889257</phone>
    <email>aldo.rinaldi@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher A Rinaldi</last_name>
      <phone>02071889257</phone>
      <email>aldo.rinaldi@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

